

Continuation Investments Limited

17 September 2014

Market Announcements Office
Australian Securities Exchange, Sydney

By E-Lodgement


Transaction Update

Continuation Investments Limited (ASX:COT) advises that work is continuing on the acquisition of leading-edge Colorado based medical technology and device company The Biofusionary Corporation Limited (TBC) as announced to the market on 29 July 2014 (Transaction).

There has been a delay to the entry into stock transfer documents with each of the shareholders of TBC and to the Transaction timetable, due mainly to TBC obtaining detailed US regulatory and tax advice. Such advice is expected to be received soon – following from that advice, it may be that certain aspects of the Transaction require restructuring in order to achieve a satisfactory outcome to all parties.

The Company shall keep investors and shareholders informed of developments.

For and on Behalf of the Board



Jeremy King
Chairman

CAPITAL STRUCTURE

Shares: 19.86m
Options: 2.25m
Cash: \$1.48m (June 2014)

BOARD & MANAGEMENT

Mr Jeremy King
Chairman

Mr Andrew Worland
Non-Executive Director

Mr David Church
Non-Executive Director

Ms Sarah Smith
Company Secretary

REGISTERED OFFICE
945 Wellington Street
West Perth
WA 6005

CONTACT DETAILS
Tel: +61 8 9322 7600
Fax: +61 8 9322 7602

SHARE REGISTRY
Automic Registry Services
7 Ventnor Avenue
West Perth
WA 6005

ASX CODE
COT